All In Biotech

Drug Trial Radar · NCT02346487

Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)

Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally

Last checked: Nov 19, 2026Latest source record: May 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,003

Actual

Start

Sep 2015

Primary completion

May 14, 2019

Study completion May 14, 2019

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
UNITAID; French Development Agency
First posted
Jan 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be carried out to provide supportive clinical data on the feasibility, efficacy, safety, and PK of LPV based therapies in routine treatment setting and will be based on the existing LPV/r pellets which already represent a clear advantage in comparison with the liquid formulation.

Conditions

  • HIV

Interventions

  • LPV/RTV pellets and AZT/3TC or ABC/3TCDrug

    Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight: * Between 3 and 5.9kg: 2 capsules twice a day * Between 6 and 9.9kg: 3 capsules twice a day * Between 10 and 13.9kg: 4 capsules twice a day * Between 14 and 19.9kg: 5 capsules twice a day * Between 20 and 24.9kg: 6 capsules twice a day Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight: * Between 3 and 5.9kg: 1 tablet twice a day * Between 6 and 9.9kg: 1.5 tablets twice a day * Between 10 and 13.9kg: 2 tablets twice a day * Between 14 and 19.9kg: 2.5 tablets twice a day * Between 20 and 24.9kg: 3 tablets twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment effectiveness at 48 weeks based on a composite endpoint of: i) virologic response <1000 copies/ml ii) being alive and iii) on study drugTime frame: 48 weeks

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • AMPATH - Moi Teaching and Referral Hospital

    Eldoret, Kenya

  • FACES Lumumba Clinic

    Kisumu, Kenya

  • Gertrude's Children Hospital

    Nairobi, Kenya

  • Kenyatta National Hospital

    Nairobi, Kenya

  • Management and Development for Health(MDH) , at Temeke and Amana Hospitals

    Dar es Salaam, Tanzania

  • Ifakara health Institute

    Morogoro, Tanzania

  • Joint Clinical research Centre

    Fort Portal, Uganda

  • Joint Clinical Research Centre

    Gulu, Uganda

  • Baylor College of Medicine, Children's Foundation - Uganda

    Kampala, Uganda

  • Joint Clinical research Centre

    Kampala, Uganda

  • Epicentre Mbarara Research Centre

    Mbarara, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.